Skip to main content
Erschienen in: Molecular Neurodegeneration 1/2013

Open Access 01.09.2013 | Poster presentation

Parkin acts as a transcription factor modulating presenilin-1 and presenilin-2 promoter transactivations

verfasst von: Eric Duplan, Jean Sévalle, Julien Viotti, Thomas Goiran, Charlotte Bauer, Paul Renbaum, Ephrat Levy-Lahad, Clément A Gautier, Olga Corti, Nathalie Leroudier, Frédéric Checler, Cristine Alves da Costa

Erschienen in: Molecular Neurodegeneration | Sonderheft 1/2013

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

Parkin is associated to autosomal recessive early-onset Parkinson's disease. Parkin acts as an E3-ubiquitin ligase involved in the proteasome-mediated degradation of various substrates. It has been suggested that pathogenic mutations of parkin, abolishing its ubiquitin-ligase activity, could explain the accumulation of proteins and lead to neuronal death by apoptosis. However, besides this function, additional parkin-dependent cellular pathways exist. We demonstrated that parkin is a direct transcriptional repressor of the tumor suppressor p53 [1]. p53 regulates the expression and functions of presenilin-1 (PS1) and presenilin-2 (PS2), two members of the gamma secretase complex involved in the production of the amyloid β peptide (Aβ) and parkin could control the homeostasis of intracellular Aβ. These findings prompted us to investigate whether parkin could control presenilins and if so, whether it is via a direct transcriptional control of PS promoters or indirectly, via p53.

Materials and methods

Experiments were conducted on TSM1 neurons, SH-SY5Y human neuroblastoma cells, human embryonic kidney 293 cells, and immortalized mouse embryonic fibroblasts invalidated or not for parkin, presenilin 1 and/or 2, p19 arf and both p19 arf p53. We also used primary cultured neurons and brain extract from mouse invalidated or not for parkin.
We did Q-PCR, Western-blot, caspases-3 activity measurement and in vitro gamma secretase assays experiments. We document by chromosome immune-precipitation, gel shift, gene reporter and mutagenesis experiments parkin direct interaction with presenilins promoters.

Results

Parkin controls presenilin 1 and 2 expressions, promoter activity, and mRNA levels ex vivo and in mouse brains. This regulation impacts on PS-dependent γ-secretase activity and presenilin-mediated control of cell death. This control is independent of parkin ubiquitin-ligase activity, does not involve p53 and is not affected by PS1 and PS2 functional interplay. Parkin binds to presenilins promoters via a consensus binding sequence that we identify and validate by functional analysis [2].

Conclusions

This study is a "framework" for the identification of novel transcriptional targets of parkin and for a better comprehension of parkin's functions.

Acknowledgements

This work was supported by the ‘Fondation pour la Recherche Médicale', the ‘Conseil Général des Alpes Maritimes', and the LABEX (excellence laboratory, program investment for the future) DISTALZ.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Literatur
1.
Zurück zum Zitat da Costa CA, et al: Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol. 2009, 11 (11): 1370-1375. 10.1038/ncb1981.PubMedCentralCrossRefPubMed da Costa CA, et al: Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol. 2009, 11 (11): 1370-1375. 10.1038/ncb1981.PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Duplan E, et al: Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. J Mol Cell Biol. 2013, 5 (2): 132-142. 10.1093/jmcb/mjt003.CrossRefPubMed Duplan E, et al: Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. J Mol Cell Biol. 2013, 5 (2): 132-142. 10.1093/jmcb/mjt003.CrossRefPubMed
Metadaten
Titel
Parkin acts as a transcription factor modulating presenilin-1 and presenilin-2 promoter transactivations
verfasst von
Eric Duplan
Jean Sévalle
Julien Viotti
Thomas Goiran
Charlotte Bauer
Paul Renbaum
Ephrat Levy-Lahad
Clément A Gautier
Olga Corti
Nathalie Leroudier
Frédéric Checler
Cristine Alves da Costa
Publikationsdatum
01.09.2013
Verlag
BioMed Central
Erschienen in
Molecular Neurodegeneration / Ausgabe Sonderheft 1/2013
Elektronische ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-8-S1-P56

Weitere Artikel der Sonderheft 1/2013

Molecular Neurodegeneration 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.